Clinical Trial Update: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a triplet regimen of tafasitamab, acalabrutinib, and obinutuzumab for previously untreated chronic lymphocytic leukemia and sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Obinutuzumab (obinutuzumab)
• tafasitamab (tafasitamab)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: RECRUITING